{"nctId":"NCT00266032","briefTitle":"Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles","startDateStruct":{"date":"2005-12"},"conditions":["Contraception"],"count":1166,"armGroups":[{"label":"Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)","type":"EXPERIMENTAL","interventionNames":["Drug: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)"]},{"label":"Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)","type":"EXPERIMENTAL","interventionNames":["Drug: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)"]},{"label":"Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)"]}],"interventions":[{"name":"Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)","otherNames":[]},{"name":"Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)","otherNames":[]},{"name":"Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy women who desire contraception\n* smokers â‰¤ 30 Years old\n\nExclusion Criteria:\n\n* Contraindication against use of hormonal contraceptives","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Days With Bleeding Including Spotting","description":"The number of bleeding days per volunteer was calculated by summing up all days with bleeding intensity spotting or worse. The primary evaluation was the comparison of the flexible extended vs the standard regimen for this primary target variable, which was done for data within the first year of treatment only. As no further comparison or testing was done, no multiplicity issue arose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":"29"},{"groupId":"OG001","value":"61","spread":"51"},{"groupId":"OG002","value":"66","spread":"27"}]}]}]},{"type":"PRIMARY","title":"Number of Unintended Pregnancies in Yaz Flexible Arm","description":"Pregnancies with conception date within 4 days after end of study medication were regarded as during treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Pearl Index","description":"The Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 2-year PI was obtained by dividing the number of pregnancies that occurred during the two years of treatment by the time (in 100 women years) that the women were under risk of getting pregnant. 95% confidence interval according to European Medicine Agency Note for guidance on clinical investigation of steroid contraceptives in women.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Unintended Pregnancies Due to Method Failure","description":"Not included in this analysis are pregnancies due to subject failure eg. non-compliance with tablet intake rules.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Adjusted Pearl Index","description":"The adjusted Pearl Index was based on pregnancies due to method failures and compliant treatment cycles, i.e. cycle length between 24 and 124 day, pill break not longer than 7 days, and number of pills taken not smaller than 90% of the number of days in that cycle minus 7 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Bleeding Excluding Spotting","description":"The number of bleeding days per volunteer was calculated by summing up all days with bleeding intensity light, normal, or heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"15"},{"groupId":"OG001","value":"24","spread":"24"},{"groupId":"OG002","value":"43","spread":"20"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding Days During One Year of Treatment in Subjects With at Least 248 Days of Exposure Normalized to 372 Days","description":"For early dropouts and pregnant subjects with an exposure period of less than 1 year but at least 248 days, the number of bleeding/spotting days was normalized to correspond to a 1-year exposure period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"29"},{"groupId":"OG001","value":"66","spread":"55"},{"groupId":"OG002","value":"71","spread":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Days by 90-day Reference Period","description":"The mean number of bleeding / spotting days, spotting-only and bleeding days was analyzed using reference periods of 90 days as recommended by the WHO.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"5.5"},{"groupId":"OG001","value":"9.0","spread":"8.6"},{"groupId":"OG002","value":"14.6","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"5.6"},{"groupId":"OG001","value":"6.3","spread":"6.5"},{"groupId":"OG002","value":"10.2","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"4.3"},{"groupId":"OG001","value":"5.1","spread":"5.8"},{"groupId":"OG002","value":"9.8","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"4.5"},{"groupId":"OG001","value":"2.6","spread":"5.6"},{"groupId":"OG002","value":"9.5","spread":"4.9"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Episodes in 90 Day Reference Period","description":"The mean number of bleeding / spotting episodes was analyzed using reference periods of 90 days as recommended by the WHO.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.7"},{"groupId":"OG001","value":"2.0","spread":"1.9"},{"groupId":"OG002","value":"3.4","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.5"},{"groupId":"OG001","value":"2.1","spread":"1.4"},{"groupId":"OG002","value":"3.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.5"},{"groupId":"OG001","value":"2.1","spread":"1.8"},{"groupId":"OG002","value":"3.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.5"},{"groupId":"OG001","value":"1.3","spread":"1.5"},{"groupId":"OG002","value":"3.2","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Days With Scheduled Versus Unscheduled Bleeding","description":"Days with scheduled and unscheduled bleeding were evaluated for extended regimens only. Unscheduled is any bleeding/spotting that occurred while taking active hormones regardless of the duration of intake, unless they occurred after tablet-free interval during days 1-4 of subsequent treatment cycle, or unless they occurred during days 1-7 of first treatment cycle. Scheduled is any bleeding/spotting that occurred during tablet-free interval, regardless of duration of tablet intake, or during next 4 days of subsequent treatment cycle.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":"14.3"},{"groupId":"OG001","value":"14.0","spread":"5.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"17.4"},{"groupId":"OG001","value":"46.6","spread":"48.4"}]}]}]},{"type":"POST_HOC","title":"Number of Unintended Pregnancies Including Pregnancies Occuring Within 14 Days After End of Study Medication.","description":"Pregnancies with conception date during treatment and within 14 days after end of study medication were included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"POST_HOC","title":"Pearl Index (FDA Criteria)","description":"Following an FDA request another PI evaluation was done for the first year of treatment only and taking into consideration also pregnancies with a conception date within 14 days after end of the study medication. Restricting the analysis to the required first year of treatment, it results in this PI estimation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":642},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Cystitis","Gastroenteritis"]}}}